SCHEMBL2037323

SCHEMBL2037323

CC(C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(=O)N[C@H](C=O)CC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ABL1 P00519 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ IDE P14735 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ RIN1 Q13671 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ CASP3 P42574 3/20 0.48
▸ CASP1 P29466 1/20 0.48
▸ CASP2 P42575 1/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ CASP8 Q14790 1/20 0.48
▸ FOLH1 Q04609 7/20 0.47
▸ MAFG O15525 1/20 0.47
▸ CAPN1 P07384 2/20 0.46
▸ PLG P00747 1/20 0.43
▸ PRSS1 P07477 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6534725 0.95 CASP3 (0.55) TDP1MEN1ABL1LMNAPKM
SCHEMBL5406043 0.92 TDP1 (0.56) TDP1MEN1ABL1LMNAPKM
SCHEMBL6534718 0.84 MAFG (0.38) TDP1MEN1ABL1LMNAPKM
SCHEMBL7577396 0.84 TDP1 (0.64) TDP1MEN1ABL1LMNAPKM
SCHEMBL8219653 0.82 CASP3 (0.53) TDP1MEN1ABL1LMNAPKM
SCHEMBL29946177 0.82 TDP1 (0.53) TDP1MEN1ABL1LMNAPKM
SCHEMBL29802482 0.82 TDP1 (0.53) TDP1MEN1ABL1LMNAPKM
SCHEMBL30313496 0.79 CASP3 (0.47) CASP3CASP1CASP2CASP7CASP8
SCHEMBL31378057 0.78 TDP1 (0.69) TDP1MEN1ABL1LMNAPKM
SCHEMBL31248180 0.78 TDP1 (0.69) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-05-08 — — US disclosed
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-04-17 — — US disclosed
US-12139744-B2 Stabilisation of biological samples QIAGEN GMBH (DE) 2024-11-12 — — US disclosed
US-12110533-B2 Stabilisation and isolation of extracellular nucleic acids QIAGEN GMBH (DE) 2024-10-08 — — US disclosed
US-20240287574-A1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS QIAGEN GMBH (DE) 2024-08-29 — — US disclosed
EP-4397770-A1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS PreAnalytiX GmbH (CH) 2024-07-10 — — EP disclosed
EP-3401406-B1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS PREANALYTIX GMBH (CH) 2023-11-29 — — EP disclosed
US-11525155-B2 Stabilisation of biological samples QIAGEN GMBH (DE) 2022-12-13 — — US disclosed
US-20220364149-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2022-11-17 — — US disclosed
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2022-05-10 — — US disclosed
US-20110159004-A1 Methods and Compositions for Preserving the Viability of Photoreceptor Cells MASSACHUSETTS EYE AND EAR INFIRMARY 2011-06-30 — — US disclosed
US-7811832-B2 Methods for preserving the viability of photoreceptor cells by anti-FAS-ligand/anti-FAS-receptor antibodies MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2010-10-12 — — US disclosed
US-20100074882-A1 METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2010-03-25 — — US disclosed
US-7592330-B2 Methods and compositions for preserving the viability of photoreceptor cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2009-09-22 — — US disclosed
US-20070287756-A1 Methods and Compositions for Preserving the Viability of Photoreceptor Cells MASSACHUSETTS EYE AND EAR INFIRMARY 2007-12-13 — — US disclosed
WO-2007019427-A2 METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS MASSACHUSETTS EYE & EAR INFIRMARY (US) 2007-02-15 — — WO disclosed
US-20070032427-A1 Methods and compositions for preserving the viability of photoreceptor cells MASSACHUSETTS EYE AND EAR INFIRMARY 2007-02-08 — — US disclosed
US-20050129684-A1 Methods and compositions for preserving the viability of photoreceptor cells MASSACHUSETTS EYE AND EAR INFIRMARY 2005-06-16 — — US disclosed
EP-1278552-A2 FUNCTIONAL MRI AGENTS FOR CANCER IMAGING RESEARCH CORPORATION TECHNOLOGIES (US) 2003-01-29 — — EP disclosed
WO-2001082976-A2 FUNCTIONAL MRI AGENTS FOR CANCER IMAGING RESEARCH CORPORATION TECHNOLOGIES (US) 2001-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 TDP1 342/4885MEN1 1662/4885ABL1 1752/4885
US-12139744-B2 Stabilisation of biological samples RNASE1, RNASEH1, EWSR1 TDP1 342/4885MEN1 1662/4885ABL1 1752/4885
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor HDGF, F11, F12 TDP1 4223/4885MEN1 1056/4885ABL1 3984/4885
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 TDP1 342/4885MEN1 1662/4885ABL1 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback